Interferon-α-induced activation of signal transducer and activator of transcription proteins in malignant melanoma

Clinical Cancer Research

Volumn 4, Issue 9, 1998, Pages 2219-2228

  Carson, William E ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; STAT1 PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; CANCER CELL CULTURE; CASE REPORT; DOSE RESPONSE; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; GENE TARGETING; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ADULT; ANTINEOPLASTIC AGENTS; DNA-BINDING PROTEINS; ELECTROPHORESIS; HELA CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON ALFA-2B; INTERFERON TYPE II; KINETICS; MALE; MELANOMA; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0031696748     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Rigel, D. S. Malignant melanoma: perspectives on incidence and its effects on awareness, diagnosis, and treatment. CA Cancer J. Clin., 46: 195-198, 1996.
2. Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., and Blum, R. H. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol., 14: 7-17, 1996.
3. Kirkwood, J. M. Melanoma. In: D. T. Devita, S. Hellman, and S. A. Rosenberg (eds.), Biologic Therapy of Cancer, pp. 388-411. Philadelphia: J. B. Lippincott, 1995.
4. Salmon, S. E., Durie, B. G., Young, L., Liu, R. M., Trown, P. W., and Stebbing, N. Effects of cloned human leukocyte interferons in the human tumor stem cell assay. J. Clin. Oncol., 1: 217-225, 1983.
5. Von Stamm, U., Brocker, E. B., Von Depka Prondzinski, M., Ruiter, D. J., Rumke, P., Broding, C., Carrel, S., and Lejeune, S. J. Effects of interferon-α (IFN-α) on the antigenic phenotype of melanoma metastases. EORTC melanoma group cooperative study no. 18852. Melanoma Res., 3: 173-180, 1993.
6. Giacomini, P., Aguzzi, A., Pestka, S., Fisher, P. B., and Ferrone, S. Modulation by recombinant DNA leukocyte (α) and fibroblast (β) interferons of the expression and shedding of HLA-and tumor-associated antigens by human melanoma cells. J. Immunol., 133: 1649-1655, 1984.
7. Agarwala, S. S., and Kirkwood, J. M. Potential uses of interferon-α2 as adjuvant therapy in cancer. Ann. Surg. Oncol., 2: 365-371, 1995.
8. Ramani, P., and Balkwill, F. R. Human interferons inhibit experimental metastases of a human melanoma cell line in nude mice. Br. J. Cancer, 58: 350-354, 1988.
9. Nagy, P., Kopper, L., Gyapay, G., Peterfy, F., and Lapis, K. Effect of interferon-α (IFNα) on various human tumor xenografts. Anti-Cancer Res., 8: 467-470, 1988.
10. Vanden Broecke, C., and Pfeffer, L. M. Characterization of interferon-α binding sites on human cell lines. J. Interferon Res., 8: 803-811, 1988.
11. Navarro, S., Colamonici, O. R., and Llombart-Bosch, A. Immunohistochemical detection of the type I interferon receptor in human fetal, adult, and neoplastic tissues. Mod. Pathol., 9: 150-156, 1996.
12. Darnell, J. E., Kerr, I. M., and Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (Washington DC), 264: 1415-1421, 1994.
13. Levy, D. E., Kessler, D. S., Pine, R., Reich, N., and Darnell, J. E. Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative control. Genes Dev., 2: 383-393, 1988.
14. Sadowski, H. B., Shuai, K., Darnell, J. E., and Gilman, M. Z. A common nuclear signal transduction pathway activated by growth and cytokine receptors. Science (Washington DC), 261: 1739-1744, 1993.
15. Fogh, J., Fogh, J. M., and Orfeo, T. One hundred and twenty seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst., 59: 2231-225, 1977.
16. Carey, T. E., Takahashi, T., Resnick, L. A., Oettgen, H. F., and Old, L. J. Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc. Natl. Acad. Sci. USA, 73: 3278-3282, 1976.
17. Schindler, C., Shuai, K., Prezioso, V. R., and Darnell, J. E. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science (Washington DC), 257: 809-813, 1992.
18. Lai, C. F., Ripperger, J., Morella, K. K., Jurlander, J., Hawley, T. S., Carson, W. E., Kordula, T., Caligiuri, M. A., Hawley, R., Fey, G. H., and Baumann, H. Receptors for IL-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements. J. Biol. Chem., 271: 13968-13975, 1996.
19. Carson, W. E., Lindemann, M. J., Baiocchi, R. A., Linett, M., Tan, J., Chan, C. C., Narula, S., and Caligiuri, M. A. The functional characterization of IL-10 receptor expression on human natural killer cells. Blood, 85: 3577-3585, 1995.
20. Reich, N., Evans, B., Levy, D., Fahey D., Knight, E., and Darnell J. E. Interferon-induced transcription of a gene encoding a 15-kDa protein depends on an upstream enhancer element. Proc. Natl. Acad. Sci. USA, 84: 6394-6398, 1987.
21. Bohrer, H., Qiu, F., Zimmerman, T., Zhang, Y., Jllmer, T., Mannel, D., Bottiger, B. W., Stern, D. M., Waldherr, R., Saeger, H-D., Zeigler, R., Bierhaus, A., Martin, E., and Nawroth, P. P. Role of NFκB in the mortality of sepsis. J. Clin. Oncol., 100: 972-985.
22. Fu, X-Y. A transcription factor with SH2 and SH3 domains is directly activated by an interferon α-induced cytoplasmic protein tyrosine kinase(s). Cell, 70: 323-335, 1992.
23. David, M., Grimly, P. M., Finbloom, D. S., and Larner, A. C. A nuclear tyrosine phosphatase down-regulates interferon-induced gene expression. Mol. Cell. Biol., 13: 7515-7521, 1993.
24. Levy, D. E., Kessler, D. S., Pine, R., and Darnell, J. E. Cytoplasmic activation of ISGF3, the positive regulator of interferon-α-stimulated transcription, reconstituted in vitro. Genes Dev., 3: 1362-1371, 1989.
25. Karner, A. C., David, M., Feldman, G. M., Igarashi, K., Hackett, R. H., Webb, D. S. A., Sweitzer, S. M., Petricoin, E. F., and Finbloom, D. S. Tyrosine phosphorylation of DNA binding proteins by multiple cytokines. Science (Washington DC), 261: 1730-1733, 1993.
26. Levy, D. E., Lew, D. J., Decker, T., Kessler, D. S., and Darnell, J. E. Synergistic interaction between interferon-α and interferon-α through induced synthesis of one subunit of the transcription factor ISGF3. EMBO J., 9: 1105-1111, 1990.
27. Improta, T., Pine, R., and Pfeffer, L. M. Interferon-γ potentiates the antiviral activity and the expression of interferon-stimulated genes induced by interferon-α in U937 cells. J. Interferon Res., 12: 87-94, 1992.
28. Ishii, Y., and Tsukagoshi, S. The synergistic effect of human recombinant interferon-α 2A in combination with interferon-γ and the induction of interferon-α 2A receptor by interferon-γ. J. Pharmacobio-Dyn., 12: 299-304, 1989.
29. Kessler, D. S., Veals, S. A., Fu, X-F., and Levy, D. E. Interferon-α regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator. Genes Dev., 4: 1753-1765, 1990.
30. Starr, R., Willson, T. A., Viney, E. M., Murray, L. J. L., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A., and Hilton, D. J. A family of cytokine-inducible inhibitors of signalling. Nature (Lond.), 387: 917-921, 1997.
31. Kurzrock, R., Rosenblum, M. G., Quesada, J. R., Sherwin, S. A., Itri, L. M., and Gutterman, J. U. Phase I study of recombinant interferon-α and recombinant interferon-γ in cancer patients. J. Clin. Oncol., 4: 1677-1683, 1986.
32. Czarniecki, C. W., Fennie, C, W., Powers, D. B., and Estell, D. A. Synergistic antiviral and anti-proliferative activities of Escherichia coli-derived human α, β, and gamma interferons. J. Virol., 49: 490-496, 1984.
33. Carlo-Stella, C., Cazzola, M., Ganser, A., Bergamaschi, G., Pedrazolli, P., Hoelzer, D., and Ascari, E. Synergistic antiproliferative effect of recombinant interferon-γ with recombinant interferon-α on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-MK, BFU-E, and CFU-GM). Blood, 72: 1293-1299, 1988.
34. Creagan, E. T., Loprinzi, C. L., Ahmann, D. L., and Schaid, D. J. A phase I-II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon-γ in patients with metastatic malignant melanoma. Cancer (Phila.), 62: 2472-2474, 1988.
35. Osanto, S., Jansen, R., Naipal, A. M. I. H., Gratma, J-W., Van Leeuwen, A., and Cleton, F. J. In vivo effects of combination treatment with recombinant interferon-γ and α in metastatic melanoma. Int. J. Cancer, 43: 1001-1006, 1989.
36. Ernstoff, M. S., Nair, S., Bahnson, R. R., Miketic, L. M., Banner, B., Gooding, W., Day, R., Whiteside, T., Hakala, T., and Kirkwood, J. M. A phase IA trial of sequential recombinant DNA-produced interferons: combination recombinant interferon γ and recombinant interferon α in patients with metastatic renal carcinoma. J. Clin. Oncol., 8: 1637-1649, 1990.
37. Opalka, B., Wandl, U. B., Becher, R., Kloke, O., Nagel-Hiemke, M., Beer, U., Seeber, S., and Niederle, N. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alone or in combination with interferon γ. Blood, 78: 2188-2193, 1991.
38. Wandl, U. B., Kloke, O., Nagel-Hiemke, M., Moritz, T., Becher, R., Opalka, B., Holtkamp, W., Bartels, H., Seeber, S., and Niederle, N. Combination therapy with interferon α-2b plus low-dose interferon γ in pretreated patients with Ph-positive chronic myelogenous leukemia. Br. J. Haematol., 81: 516-519, 1992.